{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:25:05Z","timestamp":1785835505883,"version":"3.56.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Therapeutic monoclonal antibodies against the calcitonin gene\u2010related peptide (CGRP) receptor or its ligand have changed the landscape of treatment options for migraine. Erenumab is the first and only fully human monoclonal antibody designed to target and block the CGRP receptor. It is approved by the Food and Drug Administration for preventive treatment of migraine in adults. The recommended dose of erenumab is 70\u00a0mg monthly, with guidance that some patients may benefit from the 140\u00a0mg monthly dose. There is a need for information to guide clinical practice on the comparative efficacy and safety of these two dosing options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate therapeutic and tolerability differences between erenumab 70 and 140\u00a0mg based on evidence from published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review evaluates therapeutic and tolerability differences between erenumab 70 and 140\u00a0mg based on a literature search using PubMed interface, Embase and Ovid MEDLINE(R) databases. The key search terms included migraine, AMG 334, AMG334, erenumab, erenumab\u2010aooe, and Aimovig. The search was limited to English language articles or conference abstracts published up to May 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From the literature search, we retrieved 23 relevant articles\/conference abstracts (19 articles [5 randomized, double\u2010blind studies] and 4 conference abstracts) for inclusion in this narrative review. Although the recommended starting dosage of erenumab is 70\u00a0mg, this narrative review of the literature indicates that some patients may benefit from a dosage of 140\u00a0mg erenumab once monthly\u2014especially those with difficult\u2010to\u2010treat disease and prior treatment failures. The evidence indicates that erenumab at 140\u00a0mg has a numerically better efficacy than 70\u00a0mg across a broad spectrum of migraine outcomes, including preventing progression to chronic migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cumulative data from the literature support a therapeutic gain with an increase from erenumab 70 to 140\u00a0mg and a rationale for initiating 140\u00a0mg in selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14266","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T04:12:20Z","timestamp":1644379940000},"page":"420-435","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Erenumab dosage for migraine prevention: An evidence\u2010based narrative review with recommendations"],"prefix":"10.1111","volume":"62","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"Department of Neurology Geisel School of Medicine at Dartmouth  Hanover New Hampshire USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma U.","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Neurology Mt. Sinai\u2010Icahn School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie O.","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Department of Neurology Medstar Georgetown University Hospital  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Neurology Thomas Jefferson University, Jefferson Headache Center  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Winner","sequence":"additional","affiliation":[{"name":"Premiere Research Institute Nova Southeastern University  West Palm Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda Krishna","family":"Karanam","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Private Limited  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Blumenfeld","sequence":"additional","affiliation":[{"name":"The Los Angeles Headache Center  Los Angeles California USA"},{"name":"The San Diego Headache Center  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abdrabboh","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation  East Hanover New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"Department of Neurology Medstar Georgetown University Hospital  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.127"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007452"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"e_1_2_13_8_1","volume-title":"Aimovig\u2122 United States Prescribing Information"},{"key":"e_1_2_13_9_1","volume-title":"Aimovig\u2122 Summary of Product Characteristics"},{"key":"e_1_2_13_10_1","unstructured":"Novartis marks a new era for migraine patients with the EU approval of Aimovig\u00ae a first\u2010of\u2010its\u2010kind treatment specifically designed for migraine prevention. News release. Novartis. July 30 2018. Accessed December 14 2021.https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010marks\u2010new\u2010era\u2010migraine\u2010patients\u2010eu\u2010approval\u2010aimovig\u2010first\u2010its\u2010kind\u2010treatment\u2010specifically\u2010designed\u2010migraine\u2010prevention"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419835459"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418788347"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007497"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419894559"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0233-z"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420973994"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004391"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419854082"},{"issue":"15","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.94.15_supplement.1203","article-title":"Sustained efficacy and long\u2010term safety of erenumab in patients with episodic migraine: 4+ year results of a 5\u2010year, open\u2010label treatment period (1203)","volume":"94","author":"Ashina M","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010019"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"issue":"1","key":"e_1_2_13_27_1","first-page":"104","article-title":"Effects of erenumab on patient\u2010reported outcomes in a subgroup of patients with episodic migraine and severe functional impairment","volume":"60","author":"Lipton RB","year":"2020","journal-title":"Headache"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0923-6"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13652"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420912726"},{"issue":"1","key":"e_1_2_13_31_1","first-page":"211","article-title":"Temporal response patterns to erenumab in patients with chronic migraine","volume":"39","author":"Tepper SJ","year":"2019","journal-title":"Cephalalgia"},{"issue":"1","key":"e_1_2_13_32_1","first-page":"216","article-title":"Temporal response patterns to erenumab in patients with episodic migraine","volume":"39","author":"McAllister P","year":"2019","journal-title":"Cephalalgia"},{"key":"e_1_2_13_33_1","first-page":"1","article-title":"Early use of erenumab in US real\u2010world practice","volume":"4","author":"Bogdanov A","year":"2021","journal-title":"Cephalalgia Rep"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419888222"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008743"},{"key":"e_1_2_13_36_1","volume-title":"Paying for Aimovig"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1066-0"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13459"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:28:12Z","timestamp":1762090092000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/head.14266"],"URL":"https:\/\/doi.org\/10.1111\/head.14266","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"2021-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}